The Wiskott-Aldrich syndrome (WAS) is an uncommon X-linked recessive disease characterized by thrombocytopenia, eczema and immunodeficiency. The biochemical defect of this disorder primarily affects cells derived from bone marrow. To understand better the molecular mechanisms underlying this disease and to evaluate the possibility of correcting the genetic defects in hematopoietic cells, a Moloney murine leukemia virus (MoMLV)-based retroviral vector carrying a functional Wiskott-Aldrich syndrome protein (WASp) cDNA driven by an SV40 promoter (LNSWASp) was constructed. A packaging cell line containing this vector produced a stable level of WAS protein and maintained a high titer of viral output. Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines (B-LCL) from WAS patients, which lack expression of the WAS protein, were
Introduction
Wiskott-Aldrich syndrome (WAS) is an X-linked disorder resulting in thrombocytopenia and multiple immunologic defects. 1, 2 WAS patients respond completely to successful transplantation of genetically normal allogeneic bone marrow, documenting that the underlying pathology is restricted to hematopoietic stem cells and their progeny. 3 The cloning of the normal human WAS protein gene (WASp) 4 allows consideration of gene therapy for WAS, using genetically modified autologous hematopoietic stem cells. 5, 6 Because multiple myeloid and lymphoid lineages are affected, gene correction of pluripotent hematopoietic stem cells is likely to be necessary for complete improvement, as well as to ensure enduring engraftment.
The mechanisms by which a single gene defect could transduced by the LNS-WASp retroviral vector and showed expression of WASp by Western blot. Analysis of the O-glycan pattern on cell surface glycoproteins from WAS patients' B-LCL showed an altered glycosylation pattern, due to increased activity of ␤-1,6-N-acetylglucosaminyltransferase (C2GnT). Transduction by the retroviral vector carrying the functional WASp cDNA partially restored the abnormal glycosylation pattern, and was accompanied by a decreasing C2GnT activity. These findings imply a functional linkage between the WAS protein and the expression of the glycosyltransferase involved in the O-glycosylation, and also suggest a potential gene therapy via transferring a functional WASp cDNA into hematopoietic cells for Wiskott-Aldrich syndrome. Gene Therapy (2000) 7, 314-320.
result in multiple, disparate cellular and clinical abnormalities found in patients with WAS are unknown. The WAS protein has been shown to have multiple potential functions. It has been shown that WASp is an effector of Cdc42, a GTPase involved with cytoskeletal modulation, [7] [8] [9] and it also directly binds to WIP, 10 which induces actin polymerization and redistribution in lymphoid cells, and PSTPIP, 11 which is a cytoskeletalassociated protein. In addition, WASp binds to various adapter proteins such as Nck and GRB2, suggesting a link with cellular signal transduction pathways. 8, 12, 13 These place WASp at critical junctions in cellular pathways, and provide some explanations for why mutations in WASp result in abnormalities in cellular activity, morphology, motility, and survival in multiple hematopoietic lineages. 14, 15 It is necessary to determine whether an inserted WASp cDNA can normalize each phenotypic abnormality in WASp deficient cells before clinical trials of gene therapy for WAS should be performed. In addition, adverse effects resulting from the poorly regulated expression of an ectopically inserted WASp gene also need to be evaluated.
To begin studies of WASp gene transfer, we constructed retroviral vectors carrying the normal human WASp cDNA. Expression of the WASp gene was studied in the PG13 cell line which is a murine 3T3 fibroblastbased retroviral packaging cell line, 16 and in EBV-transformed B lymphoblastoid cell lines (B-LCL) from WAS patients. Effects of WASp expression on the correction of the level of glycosylase activity and the aberrant core glycoprotein pattern associated with WASp on the EBVtransformed B lymphoblastoid cell lines were carefully examined.
Results

Construction of retroviral vectors and characterization of packaging cell lines
The LNS-WASp vector containing a normal human WASp cDNA was constructed (Figure 1a ) in Moloney murine leukemia virus (MoMLV)-based LNSX vector backbone. In such a vector, the WASp cDNA is under the control of a relatively weaker SV40 promoter and the neo gene is under the control of a stronger MoMLV LTR promoter. Our result showed that when this vector was packaged in a PG13 packaging cell line, viral output of such a packaging cell line maintained at a stable level (10 6 c.f.u./ml) following at least eight passages. In addition, the expression of WAS protein in the PG13/LNS-WASp packaging cell lines was also at a stable level (data not shown).
To confirm that the retroviral vector LNS-WASp in a P-labeled XbaI/BglII WASP cDNA fragment, the expected fragment sizes of 3.9 kb and 4.8 kb from the retroviral vector carrying the WASP cDNA were detected (Figure 1b) .
Detection of the WAS protein in CRIM negative B-LCLs followed by retrovirus mediated gene transfer Protein lysates from five WAS patients' EBV-transformed B-LCL were analyzed by Western blot analysis using a rabbit anti-human WAS protein serum. One patient (P3) showed an absence of the WAS cross-reaction protein band (CRIM negative) when the membrane was hybridized with the rabbit anti-WASp anti-serum ( Figure  2a ). After this particular cell line (P3) and other two CRIM-positive cell lines from WAS patients (P1 and P2, data not shown) were transduced with either viral supernatant from PG13/LNS-WASp or that of a negative control PG13/LN, the protein lysates were again subjected to Western blot analysis. Results showed that a strong band of 68 kDa was present in LNS-WASp-transduced cells (P3/LNSWASp) but not in LN-transduced cells (P3/LN) ( Figure 2b ). To confirm the presence of the full-
Figure 2 Screening for WASp CRIM-negative cell lines from patients' EBV-transformed B-LCLs and the expression of the WASp in a transduced CRIM negative cell line. (a) Protein lysates from five WAS patients' derived B-LCL (labeled P1-P5) were subjected to Western blot analysis using a rabbit anti-human WAS protein serum. Patient 3 (P3) showed an absence of the WASp cross-reactive protein band. (b) Western blot analysis of the expression of WAS protein in B-LCLs from a normal individual (Normal), WAS patients (P1, P2, P3) and cells from P3 transduced by the control vector LN (P3/LN) or by the LNS-WASp vector (P3/LNSWASp). Arrows point to the 68 kDa WASp bands.
length proviral integrant carrying the WASP cDNA in the transduced patient's B-LCL, genomic DNA was extracted and subjected to Southern blot analysis. A band of 3.9 kb or 4.8 kb was shown when the DNA was digested with either SstI or KpnI respectively, but not in the negative controls (Figure 1c) .
Analysis of the O-glycans and the ␤-1,6-Nacetylglucosaminyltransferase activities in a normal and a WAS EBV-transformed B-LCL Two major O-glycan core structures, the Gal␤1-3GalNA-cOH (core 1 structure) and the Gal␤1-3(Gal␤1-4GlcNAc␤1-6)GalNAcOH (core 2 structure), are present in total cellular glycoproteins from lymphocytes. 17 It has been previously reported that the enzyme activity of ␤-1,6-N-acetylglucosaminyltransferase (C2GnT), which a key enzyme that converts the glycans from the core 1 structure into the core 2 structure, was significantly increased in the cells from WAS patients. The increased C2GnT activity results in an elevated ratio of core 2 to core 1 O-glycan proteins in T lymphocytes from WAS patients compared with that of normal T lymphocytes. 17 We also analyzed the C2GnT enzyme activity in extracts from the EBV-transformed B-LCL from a normal donor, two WAS donors (P2, P3) and the same two WAS donors' cells (P2, P3) that were transduced with the LNSWASp retroviral vector ( Table 1) . The results showed that in this normal individual, the C2GnT enzyme activity was at a level of 0.09 nmol/mg protein/h. However, in the WAS patients, the enzyme activity was increased to 0.59 nmol/mg protein/h for patient 2 and 0.45 nmol/mg protein/h for patient 3. Finally, in the LNS-WASp-transduced cells, the enzyme activity had decreased to 0.24 nmol/mg protein/h and 0.18 nmol/mg protein/h for patient 2 and patient 3, respectively. Thus we conclude that C2GnT activity in patients' EBV-transduced cells was elevated and that the level of enzyme activity can be partially corrected in such cells when they were transduced with a functional WASp gene.
To confirm this result further, O-glycans prepared from one normal individual (Normal) and two patients' (P2 and P3) B-LCLs were subject to HPLC analysis ( Figure  3 ). The HPLC profile (from P2 as an example) clearly indicated an increased ratio of O-glycan core 2 structure to core 1 structure in this patient's B-LCL (Figure 3b ) (0.98), compared with that of a normal individual ( Figure  3a ) (0.10). However, when the same patient's B-LCL were transduced with the retroviral vector carrying the functional WASp cDNA, the ratio of O-glycan core 2 structure to core 1 structure was significantly reduced (Figure 3c ) (0.32). These results indicate that both the elevated C2GnT enzyme activity and the aberrant O-glycan pattern in the patient's B-LCL were partially corrected through the introduction of functional WASp cDNA. Sequence analysis showed that this patient (P2) has a relatively common missense mutation of G257A (Val75Met). 18 These results combined together indicate that in WAS patient cells, the C2GnT enzyme activity was elevated and thus, the relative amount of core 2 structure was increased. These values were significantly reduced when these cells were genetically corrected by the retroviral vector carrying a functional WASp cDNA. 
Discussion
The WAS protein is a multi-faceted molecule and is involved in many biological functions including immunological responses, actin modulation and signal transduction. Defects of blood cells found in WAS patients include restricted antigen responsiveness of T
Figure 4 Diagram of the two major O-glycan core structures present in cellular glycoproteins from lymphocytes.
Gene Therapy lymphoid cells, loss of surface sialoglycoproteins, abnormal level of glycosyltransferase, and paucity of surface microvilli in T cells. 14, 15, 19 Recent studies showed that T cell defects of cytoskeletal organization are a primary cause underlying WAS immunological deficiencies. 20 T lymphocytes from a transgenic mouse model over-expressing C2GnT enzyme, demonstrated decreased T-B cell immunological interactions due to the increased level of glycan core 2 structure in CD43 molecules. 21 These findings suggest that the ratio of core 1 and core 2 glycan structure on cell surface glycoprotein molecules affect cellular functions in accordance with the skewed ratio caused by the increased level of C2GnT enzyme activity in WASp-deficient cells. In addition, we showed that expression of the functional WASp molecules in both WAS patients' cells studied here resulted in a decreased C2GnT enzyme activity and partial normalization of the ratio of core 2 to core 1 structure molecules. It is not clear why this response was only at a partial level. We hypothesize that a total normalization may require expression of the WAS protein at a specific optimal level.
The defect of WAS protein causes severely shortened survival of platelets in the circulation, resulting in the characteristic thrombocytopenia. WAS patients may also have moderately decreased numbers of T lymphocytes, but the numbers of circulating granulocytes and erythrocytes are normal. However, women who are obligate carriers of WAS, while asymptomatic, demonstrate that the defects of WASp do affect cells of multiple lineages, based on the findings of a skewed X-inactivation pattern in essentially every myeloid and lymphoid lineage that has been studied. 15, 22 Wengler and co-workers 23 have recently demonstrated skewed X-inactivation patterns in early hematopoietic progenitor cells (CD34 + cells) isolated from bone marrow of carriers, suggesting a deleterious effect of mutant WAS allele in these primitive cells. These findings imply that the expression of the defective WAS allele may affect the production or survival of relatively primitive progenitor or even stem cells.
The studies reported here represent a first step toward development of a gene therapy approach toward WAS. Many questions remain to be addressed concerning the possible beneficial and deleterious effects of retrovirus-mediated gene transfer of the WASp cDNA before clinical trials can begin.
Materials and methods
Cells and cell lines
The murine fibroblast packaging cell line PG13 containing a gibbon ape leukemia virus envelope protein, 16 and a human adenocarcinoma cell line HT29 were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). GP+E86 24 a murine fibroblast ecotropic packaging cell line was a generous gift from A Bank (Columbia University, New York, NY, USA). All cells except GP+E86 were grown in Dulbecco's modified Eagles's medium (DMEM) (GIBCO-BRL, Grand Island, NY, USA) containing 10% (v/v) heat inactivated fetal bovine serum (Irvine Scientific, Santa Ana, CA, USA) and supplemented with l-glutamine at 2 mmol/l, penicillin/streptomycin at 100 U/ml (D-10). For GP+E86 cells, 10% newborn calf serum (Irvine Scientific) was used instead of fetal bovine serum. Cells were cultured at 37°C in a 5% CO 2 humidified incubator.
Whole blood samples from normal donors or WAS patients were collected at the time of diagnosis with approved consent procedures by the Committee on Clinical Investigation, Childrens Hospital Los Angeles. Lowdensity mononuclear cells were obtained by density gradient centrifugation with Ficoll-Hypaque (Pharmacia, Piscataway, NJ, USA) as described previously. 25 EBVtransformed B-LCL were generated by inoculating 10 7 freshly obtained mononuclear cells with EBV-containing supernatant conditioned by the marmoset line B95-8 (ATCC) in the presence of 1 g/ml cyclosporin A (Pharmacia). These cell lines were propagated in RPMI-1640 medium (Irvine Scientific) with 10% (v/v) heat inactivated fetal bovine serum and supplemented with l-glutamine at 2 mmol/l, penicillin/streptomycin at 100 U/ml (R-10). The LNS-WASp retroviral vector, which carries a neomycin phosphotransferase II gene, was first transfected into GP+E86 cells using DOTAP Transfection Reagent (Boehringer Mannheim, Indianapolis, IN, USA). The transiently produced viruses were collected after 48 h and used to transduce PG13 packaging cells. The transduced PG13 cells were selected in 0.5 mg/ml G418 active compound (GIBCO-BRL). Individual clones were isolated, expanded, and screened for viral titer on HT29 cells with serial dilution of viral supernatant. A clone producing high titer of LNS-WASp at 3 × 10 6 G418-resistant colonyforming unit (c.f.u.) per ml was obtained. This packaging clone was then expanded, and retroviral supernatant was collected from D-10 medium conditioned by confluent monolayers for 48 h at 32°C.
Retroviral vectors
Transduction of EBV cell lines
EBV-transformed B-lymphoblastoid cell lines (B-LCL) from normal donors and WAS patients were transduced with 5 ml of supernatant from either PG13/LN or PG13/LNS-WASp packaging cell lines three times during a period of 3 days. After an additional 2-day incubation, transduced cells were selected in R10 medium, containing 0.5 mg/ml of G418 for 2 weeks and then further expanded in R10 medium.
Southern blot analysis
Genomic DNA from cell pellets was isolated as previously described. 27 Fifteen to twenty micrograms of genomic DNA was digested with appropriate restriction endonucleases and 10 g DNA were then loaded in each lane of a 0.8% agarose gel. Following electrophoresis, DNA was transferred from the gel to a nylon membrane (Pall Biosupport, Glen Cove, NY, USA) and UV crosslinked. The hybridization probe was an 800 bp XbaI/BglII fragment of the WASP cDNA (see Figure 1a ) labeled with ␥- Western blot EBV cell lines from clinically diagnosed patients at the Childrens Hospital Los Angeles were subject to Western blot analysis using a rabbit anti-human WASp immunoglobulin (IgG) as a primary antibody (Derry and Francke, unpublished) followed by hybridization of the membrane with horse anti-rabbit IgG conjugated with streptavidinalkaline phosphatase. Five to ten million cells were lysed in 25 l of 1% NP40 protein lysis buffer containing 100 U/ml of phenylmethylsulfonyl fluoride (PMSF), 1 g/ml of aprotinin and 0.5% sodium deoxycholate proteinase inhibitors at room temperature for 10 min. Sixty g protein lysate from each EBV cell line were loaded in 10% Tris-HCl acrylamide gels and electrophoresed at 100 V for 3 h. Protein molecules were transferred to a nitrocellulose membrane using a Bio-Rad gel transfer apparatus (BioRad, Hercules, CA, USA). The membrane was blocked with 3% BSA in TBST buffer (20 mm Tris-HCl pH 7.5, 0.5 m NaCl, 0.05% Tween-20) for 1 h, followed by incubation with the primary rabbit-anti-WASp IgG antibody and a secondary alkaline phosphatase-conjugated horse anti-rabbit IgG antibody in 3% BSA/TBST. The membrane was developed in AP buffer (0.1 m TrisHCl, pH 9.5, 0.1 m NaCl, 5 mm MgCl 2 , 10 g/ml NBT, 5 g/ml, BCIP) for 5 to 10 min. One CRIM (cross-reactive immunological material)-negative B-LCL and two other CRIM-positive B-LCLs from WAS patients were selected for gene transfer with the LN and LNS-WASp retroviral vectors and subsequently subjected to Western blot analysis again as described above.
Analysis of the O-glycans from the EBV-transformed B-LCL
O-glycan analysis was performed as described 28 with slight modification. Cells (1-2 × 10 7 cells) were metabolically labeled with 3 H glucosamine (10 Ci/ml) in RPMI 1640 (without glucose), supplemented with 10% dialyzed fetal calf serum for 24 h. The labeled cells, containing approximately 0.9-1.2 × 10 7 c.p.m., were harvested, washed with PBS, and then collected by centrifugation. Cell lipids were removed by extracting the cell pellets with chloroform-methanol (2:1), total cell glycoproteins were precipitated by centrifugation, and further digested with Pronase (Sigma, St Louis, MO, USA) for 24 h at 37°C in a toluene atmosphere. Each digest was boiled for 5 min to inactivate the remaining pronase activity, centrifuged at 735 g for 5 min, and then the supernatant was applied to a Sephadex G-50 column (1.5 × 100 cm, Pharmacia, superfine) which had been previously equilibrated (50 mm NH 4 HCO 3 , pH 7.4). High molecular weight glycopeptides were pooled, desalted, and subjected to ␤-elimination (0.05 m NaOH-1 m NaBH 4 , 42°C, 24 h) to release the O-linked oligosaccharides. The released O-glycans were separated from the remaining glycopeptide by gel filtration using the same type of Sephadex G-50 column and then subjected to a mild acid hydrolysis (2 m acetic acid, 80°C, 3 h) to remove sialic acids. The final products of neutralized oligosaccharides were analyzed by a Gilson HPLC apparatus on a Varian MicroPak column AX-5 (Varian, Harbor City, CA, USA). Structures of the oligosaccharides were deduced from their elution positions relative to that of the standard oligosaccharides. The two standard oligosaccharides, Gal␤-3GalNAcOH (core 1 structure) and Gal␤1-3(Gal␤1-4GlcNAc␤1-6) GalNAcOH (core 2 structure), were used to calibrate the HPLC column.
Analysis of the enzyme activity of ␤-1,6-N-acetylglucosaminyltransferase was performed as previously described. 29 Briefly, 1 × 10 7 cells were lysed in 0.4% TritonX-100, 0.9% NaCl and clarified by centrifugation at 5000 g. The lysate at a protein concentration of 10 mg/ml was used for this assay. A reaction mixture containing 50 mm MES (pH 7.0), 100 mm GlcNAc (Sigma), 1 mm UDPGlcNAc (Sigma), 1 Ci UDP-3H-GlcNAc (NEN, Boston, MA, USA), 1 mm p-nitrophenyl-Galb(beta)1-3GalNAc (Sigma) and 25 l of cell lysate was in a total volume of 50 l and such reaction mixture was then incubated for 1 h at 37°C. Radiolabeled reaction products were purified by C-18 Sep-Pak (Waters, Milford, MA, USA) column chromatography and then counted for radioactivities.
